Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis

Progress in Retinal and Eye Research

Volumn 48, Issue , 2015, Pages 82-118

  Daruich, Alejandra ^a   Matet, Alexandre ^a   Dirani, Ali ^a   Bousquet, Elodie ^b,c,d,e   Zhao, Min ^b,c,d   Farman, Nicolette ^b,c,d   Jaisser, Frédéric ^b,c,d   Behar Cohen, Francine ^a,b,c,d  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b SORBONNE UNIVERSITÉ   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔTEL DIEU   (France)

Author keywords

Central serous chorioretinopathy; Corticosteroids; Glucocorticoids; Mineralocorticoid receptor; Mineralocorticoid receptor antagonists; Physiopathology; Retina

Indexed keywords

ALDOSTERONE RECEPTOR; CORTICOSTEROID; MINERALOCORTICOID RECEPTOR; VASCULOTROPIN ANTIBODY; GLUCOCORTICOID; MINERALOCORTICOID ANTAGONIST;

AUTOFLUORESCENCE; CENTRAL SEROUS RETINOPATHY; CHOROID; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DOME SHAPED MACULA; ENDOCRINE SYSTEM; ESOPHAGUS DISEASE; EYE BLOOD FLOW; FLUORESCENCE IMAGING; GENETIC PREDISPOSITION; HEMANGIOMA; HUMAN; HYPERTENSION; INDOCYANINE GREEN ANGIOGRAPHY; MENTAL DISEASE; META ANALYSIS (TOPIC); MULTIMODAL IMAGING; NONHUMAN; OPTIC DISK ANOMALY; PACHYCHOROID NEOVASCULOPATHY; PARASYMPATHETIC TONE; PATHOGENESIS; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PHYSIOTHERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SLEEP DISORDER; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; STOMACH DISEASE; SUBRETINAL NEOVASCULARIZATION; SYMPATHETIC TONE; ANIMAL; CENTRAL SEROUS CHORIORETINOPATHY; DISEASE MODEL; GENETICS;

ADRENAL CORTEX HORMONES; ANIMALS; CENTRAL SEROUS CHORIORETINOPATHY; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; GLUCOCORTICOIDS; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RISK FACTORS;

EID: 84939257073     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2015.05.003     Document Type: Review

References (343)

1. Agarwal A. Gass's Atlas of Macular Diseases 2012, Elsevier. fifth ed.
2. Ahlers C., Geitzenauer W., Stock G., Golbaz I., Schmidt-Erfurth U., Prünte C. Alterations of intraretinal layers in acute central serous chorioretinopathy. Acta Ophthalmol. 2009, 87:511-516.
3. Ahnoux-Zabsonre A., Quaranta M., Mauget-Faÿsse M. Prevalence of Helicobacter pylori in central serous chorioretinopathy and diffuse retinal epitheliopathy: a complementary study. J.Fr. Ophtalmol. 2004, 27:1129-1133.
4. Aliferis K., Petropoulos I.K., Farpour B., Matter M.A., Safran A.B. Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors?. Ophthalmologica 2012, 227:85-89.
5. Alkin Z., Ozkaya A., Agca A., Yazici A.T., Demirok A. Early visual and morphologic changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy. J.Ocul. Pharmacol. Ther. 2014, 30:359-365.
6. Amalric P., Gourinat P., Rebière P. Is central serous choroiditis sometimes hereditary?. Bull. Soc. Ophtalmol. Fr. 1971, 71:163-168.
7. Arevalo J.F., Espinoza J.V. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up. Graefes Arch. Clin. Exp. Ophthalmol. 2011, 249:1159-1166.
8. Artunay O., Yuzbasioglu E., Rasier R., Sengul A., Bahcecioglu H. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr. Eye Res. 2010, 35:91-98.
9. Ayata A., Tatlipinar S., Kar T., Unal M., Ersanli D., Bilge A.H. Near-infrared and short-wavelength autofluorescence imaging in central serous chorioretinopathy. Br. J. Ophthalmol. 2009, 93:79-82.
10. Aydin E. The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy. J.Ocul. Pharmacol. Ther. 2013, 29:10-13.
11. Baek J., Park Y.-H. Optical density ratio in the subretinal fluid: differentiating chronic central serous chorioretinopathy and polypodial choroidal vasculopathy. Am. J. Ophthalmol. 2015, 159:386-392.
12. Bae S.H., Heo J.W., Kim C., Kim T.W., Lee J.Y., Song S.J., Park T.K., Moon S.W., Chung H. Arandomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am. J. Ophthalmol. 2011, 152. 784.e2-792.e2.
13. Bandello F., Incorvaia C., Rosa N., Parmeggiani F., Costagliola C., Sebastiani A. Bilateral central serous chorioretinopathy in a patient treated with systemic cortico-steroids for non-Hodgkin lymphoma. Eur. J. Ophthalmol. 2002, 12:123-126.
14. Baran N.V., Gürlü V.P., Esgin H. Long-term macular function in eyes with central serous chorioretinopathy. Clin. Exp. Ophthalmol. 2005, 33:369-372.
15. Barrett Mueller K., Lu Q., Mohammad N.N., Luu V., McCurley A., Williams G.H., Adler G.K., Karas R.H., Jaffe I.Z. Estrogen receptor inhibits mineralocorticoid receptor transcriptional regulatory function. Endocrinology 2014, 155:4461-4472.
16. Bauersachs J. The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects?. Eur. Heart J. 2013, 34:2426-2428.
17. Baumal C.R., Martidis A., Truong S.N. Central serous chorioretinopathy associated with periocular corticosteroid injection treatment for HLA-B27-associated iritis. Arch. Ophthalmol. 2004, 122:926-928.
18. Behnia M., Khabazkhoob M., Aliakbari S., Abadi A.E., Hashemi H., Pourvahidi P. Improvement in visual acuity and contrast sensitivity in patients with central serous chorioretinopathy after macular subthreshold laser therapy. Retina (Phila. Pa.) 2013, 33:324-328.
19. Bevis T., Ratnakaram R., Smith M.F., Bhatti M.T. Visual loss due to central serous chorioretinopathy during corticosteroid treatment for giant cell arteritis. Clin. Exp. Ophthalmol. 2005, 33:437-439.
20. Bousquet E., Beydoun T., Rothschild P.-R., Bergin C., Zhao M., Batista R., Brandely M.-L., Couraud B., Farman N., Gaudric A., Chast F., Behar-Cohen F. Spironolactone for non-resolving central serous chorioretinopathy: a randomized controlled cross-over study. Retina (Phila. Pa.) 2015, (in press).
21. Bousquet E., Beydoun T., Zhao M., Hassan L., Offret O., Behar-Cohen F. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina (Phila. Pa.) 2013, 33:2096-2102.
22. Bouzas E.A., Karadimas P., Pournaras C.J. Central serous chorioretinopathy and glucocorticoids. Surv. Ophthalmol. 2002, 47:431-448.
23. Bouzas E.A., Moret P., Pournaras C.J. Central serous chorioretinopathy complicating solar retinopathy treated with glucocorticoids. Graefes Arch. Clin. Exp. Ophthalmol. 1999, 237:166-168.
24. Bouzas E.A., Scott M.H., Mastorakos G., Chrousos G.P., Kaiser-Kupfer M.I. Central serous chorioretinopathy in endogenous hypercortisolism. Arch. Ophthalmol. 1993, 111:1229-1233.
25. Brancato R., Pratesi R., Leoni G., Trabucchi G., Vanni U. Histopathology of diode and argon laser lesions in rabbit retina. A comparative study. Invest. Ophthalmol. Vis. Sci. 1989, 30:1504-1510.
26. Brancato R., Scialdone A., Pece A., Coscas G., Binaghi M. Eight-year follow-up of central serous chorioretinopathy with and without laser treatment. Graefes Arch. Clin. Exp. Ophthalmol. 1987, 225:166-168.
27. Brandl C., Helbig H., Gamulescu M.A. Choroidal thickness measurements during central serous chorioretinopathy treatment. Int. Ophthalmol. 2014, 34:7-13.
28. Briet M., Schiffrin E.L. Vascular actions of aldosterone. J.Vasc. Res. 2013, 50:89-99.
29. Broadhead G.K., Chang A. Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2015 Jun, 253(6):979-981.
30. Brodie F.L., Charlson E.S., Aleman T.S., Salvo R.T., Gewaily D.Y., Lau M.K., Farren N.D., Engelhard S.B., Pistilli M., Brucker A.J. Obstructive sleep apnea and central serous chorioretinopathy. Retina (Phila. Pa.) 2015, 35:238-243.
31. Browning D.J. Nadolol in the treatment of central serous retinopathy. Am. J. Ophthalmol. 1993, 116:770-771.
32. Brown N.J. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat. Rev. Nephrol. 2013, 9:459-469.
33. Bujarborua D. Long-term follow-up of idiopathic central serous chorioretinopathy without laser. Acta Ophthalmol. Scand. 2001, 79:417-421.
34. Bujarborua D., Chatterjee S., Choudhury A., Bori G., Sarma A.K. Fluorescein angiographic features of asymptomatic eyes in central serous chorioretinopathy. Retina (Phila. Pa.) 2005, 25:422-429.
35. Bujarborua D., Nagpal P.N., Deka M. Smokestack leak in central serous chorioretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2010, 248:339-351.
36. Burumcek E., Mudun A., Karacorlu S., Arslan M.O. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology 1997, 104:616-622.
37. Caccavale A., Romanazzi F., Imparato M., Negri A., Morano A., Ferentini F. Low-dose aspirin as treatment for central serous chorioretinopathy. Clin. Ophthalmol. 2010, 4:899-903.
38. Caillaux V., Gaucher D., Gualino V., Massin P., Tadayoni R., Gaudric A. Morphologic characterization of dome-shaped macula in myopic eyes with serous macular detachment. Am. J. Ophthalmol. 2013, 156. 958.e1-967.e1.
39. Carlesimo S.C., Piazzi G., Leone C., Di Santo L., Coccanari dè Fornari M.A. Masuda's central serous chorioretinopathy (C.S.C.R.) and its somatic investment in Narcissism: our observations on new psychiatric nosography. Clin. Ter. 2014, 165:27-30.
40. Carrai P., Pichi F., Bonsignore F., Ciardella A.P., Nucci P. Wide-field spectral domain-optical coherence tomography in central serous chorioretinopathy. Int. Ophthalmol. 2015 Apr, 35(2):167-171.
41. Carvalho-Recchia C.A., Yannuzzi L.A., Negrão S., Spaide R.F., Freund K.B., Rodriguez-Coleman H., Lenharo M., Iida T. Corticosteroids and central serous chorioretinopathy. Ophthalmology 2002, 109:1834-1837.
42. Casella A.M.B., Berbel R.F., Bressanim G.L., Malaguido M.R., Cardillo J.A. Helicobacter pylori as a potential target for the treatment of central serous chorioretinopathy. Clin. (Sao Paulo) 2012, 67:1047-1052.
43. Castro-Correia J., Coutinho M.F., Rosas V., Maia J. Long-term follow-up of central serous retinopathy in 150 patients. Doc. Ophthalmol. 1992, 81:379-386.
44. Chaine G., Haouat M., Menard-Molcard C., Favard C., Vignal-Clermont C., Campinchi-Tardy F., Massin P., Gaudric A., Badelon I., Nicolon L., Sabatier P., Guillevin L. Central serous chorioretinopathy and systemic steroid therapy. J.Fr. Ophtalmol. 2001, 24:139-146.
45. Chan W.-M., Lai T.Y.Y., Lai R.Y.K., Liu D.T.L., Lam D.S.C. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 2008, 115:1756-1765.
46. Chan W.-M., Lai T.Y.Y., Liu D.T.L., Lam D.S.C. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am. J. Ophthalmol. 2007, 143:977-983.
47. Chan W.M., Lam D.S.C., Lai T.Y.Y., Tam B.S.M., Liu D.T.L., Chan C.K.M. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br. J. Ophthalmol. 2003, 87:1453-1458.
48. Chan W.M., Lam D.S.C., Lai T.Y.Y., Yuen K.S.C., Liu D.T.L., Chan C.K.M., Chen W.Q. Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin. Am. J. Ophthalmol. 2003, 136:836-845.
49. Chan W.M., Lim T.-H., Pece A., Silva R., Yoshimura N. Verteporfin PDT for non-standard indications-a review of current literature. Graefes Arch. Clin. Exp. Ophthalmol. 2010, 248:613-626.
50. Cheng L.L., Kwok A.K.H., Wat N.M.S., Neoh E.L., Jon H.C.K., Lam D.S.C. Graft-vs-host-disease-associated conjunctival chemosis and central serous chorioretinopathy after bone marrow transplant. Am. J. Ophthalmol. 2002, 134:293-295.
51. Chen S.-N., Chen Y.-C., Lian I. Increased risk of coronary heart disease in male patients with central serous chorioretinopathy: results of a population-based cohort study. Br. J. Ophthalmol. 2014, 98:110-114.
52. Chen S.-N., Hwang J.-F., Tseng L.-F., Lin C.-J. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology 2008, 115:2229-2234.
53. Chinenov Y., Gupte R., Rogatsky I. Nuclear receptors in inflammation control: repression by GR and beyond. Mol. Cell. Endocrinol. 2013, 380:55-64.
54. Chinskey N.D., Johnson M.W. Treatment of subretinal fluid associated with dome-shaped macula. Ophthalmic Surg. Lasers Imaging Retina 2013, 44:593-595.
55. Chumbley L.C., Frank R.N. Central serous retinopathy and pregnancy. Am. J. Ophthalmol. 1974, 77:158-160.
56. Chung H., Kim K.-H., Kim J.-G., Lee S.Y., Yoon Y.H. Retinal complications in patients with solid organ or bone marrow transplantations. Transplantation 2007, 83:694-699.
57. Chung Y.-R., Seo E.J., Lew H.M., Lee K.H. Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye (Lond.) 2013, 27:1339-1346.
58. Cohen D., Gaudric A., Coscas G., Quentel G., Binaghi M. Diffuse retinal epitheliopathy and central serous chorioretinopathy. J.Fr. Ophtalmol. 1983, 6:339-349.
59. Conrad R., Geiser F., Kleiman A., Zur B., Karpawitz-Godt A. Temperament and character personality profile and illness-related stress in central serous chorioretinopathy. ScientificWorldJournal 2014, 2014:631687.
60. Conrad R., Weber N.F., Lehnert M., Holz F.G., Liedtke R., Eter N. Alexithymia and emotional distress in patients with central serous chorioretinopathy. Psychosomatics 2007, 48:489-495.
61. Cook C.S., Berry L.M., Bible R.H., Hribar J.D., Hajdu E., Liu N.W. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab. Dispos. 2003, 31:1448-1455.
62. Cotticelli L., Borrelli M., D'Alessio A.C., Menzione M., Villani A., Piccolo G., Montella F., Iovene M.R., Romano M. Central serous chorioretinopathy and Helicobacter pylori. Eur. J. Ophthalmol. 2006, 16:274-278.
63. Cousins L., Rigg L., Hollingsworth D., Meis P., Halberg F., Brink G., Yen S.S. Qualitative and quantitative assessment of the circadian rhythm of cortisol in pregnancy. Am. J. Obstet. Gynecol. 1983, 145:411-416.
64. Dang Y., Mu Y., Zhao M., Li L., Guo Y., Zhu Y. The effect of eradicating Helicobacter pylori on idiopathic central serous chorioretinopathy patients. Ther. Clin. Risk Manag. 2013, 9:355-360.
65. Dang Y., Sun X., Xu Y., Mu Y., Zhao M., Zhao J., Zhu Y., Zhang C. Subfoveal choroidal thickness after photodynamic therapy in patients with acute idiopathic central serous chorioretinopathy. Ther. Clin. Risk Manag. 2014, 10:37-43.
66. de Jong E.K., Breukink M.B., Schellevis R.L., Bakker B., Mohr J.K., Fauser S., Keunen J.E., Hoyng C.B., den Hollander A.I., Boon C.J. Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology 2015 Mar, 122(3):562-570.
67. Delori F.C., Dorey C.K., Staurenghi G., Arend O., Goger D.G., Weiter J.J. Invivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest. Ophthalmol. Vis. Sci. 1995, 36:718-729.
68. Desai U.R., Alhalel A.A., Campen T.J., Schiffman R.M., Edwards P.A., Jacobsen G.R. Central serous chorioretinopathy in African Americans. J.Natl. Med. Assoc. 2003, 95:553-559.
69. Desmettre T., Devoisselle J.M., Mordon S. Fluorescence properties and metabolic features of indocyanine green (ICG) as related to angiography. Surv. Ophthalmol. 2000, 45:15-27.
70. Dirani A., Matet A., Beydoun T., Mantel I., Behar-Cohen F. Resolution of foveal detachment in dome-shaped macula after treatment by spironolactone: report of two cases and mini-review of the literature. Clin. Ophthalmol. 2014, 8:999-1002.
71. Eandi C.M., Ober M., Iranmanesh R., Peiretti E., Yannuzzi L.A. Acute central serous chorioretinopathy and fundus autofluorescence. Retina (Phila. Pa.) 2005, 25:989-993.
72. Edalati K., Roesch M.T., Buchanan M.L., Teeter M., Maberley D.A. Central serous chorioretinopathy and idiopathic nonhistaminergic angioedema. Can. J. Ophthalmol. 2009, 44:606-607.
73. Ellabban A.A., Tsujikawa A., Ooto S., Yamashiro K., Oishi A., Nakata I., Miyake M., Akagi-Kurashige Y., Ueda-Arakawa N., Arichika S., Yoshitake S., Takahashi A., Yoshimura N. Focal choroidal excavation in eyes with central serous chorioretinopathy. Am. J. Ophthalmol. 2013, 156:673-683.
74. Eom Y., Oh J., Kim S.-W., Huh K. Systemic factors associated with central serous chorioretinopathy in Koreans. Korean J. Ophthalmol. 2012, 26:260-264.
75. Errera M.-H., Kohly R.P., da Cruz L. Pregnancy-associated retinal diseases and their management. Surv. Ophthalmol. 2013, 58:127-142.
76. Ezra N., Taban M., Behroozan D. Central serous chorioretinopathy associated with topical corticosteroids in a patient with psoriasis. J.Drugs Dermatol 2011, 10:918-921.
77. Falkenstein E., Norman A.W., Wehling M. Mannheim classification of nongenomically initiated (rapid) steroid action(s). J.Clin. Endocrinol. Metab. 2000, 85:2072-2075.
78. Farman N., Maubec E., Poeggeler B., Klatte J.E., Jaisser F., Paus R. The mineralocorticoid receptor as a novel player in skin biology: beyond the renal horizon?. Exp. Dermatol 2010, 19:100-107.
79. Farzan K., Rezaei L., Ghanbari H., Dehghani A. Central serous chorioretinopathy following kidney transplantation. Saudi J. Kidney Dis. Transpl. 2014, 25:615-620.
80. Fawzi A.A., Cunningham E.T. Central serous chorioretinopathy after bone marrow transplantation. Am. J. Ophthalmol. 2001, 131:804-805.
81. Fawzi A.A., Holland G.N., Kreiger A.E., Heckenlively J.R., Arroyo J.G., Cunningham E.T. Central serous chorioretinopathy after solid organ transplantation. Ophthalmology 2006, 113. 805.e5-813.e5.
82. Feldman R.D., Gros R. Vascular effects of aldosterone: sorting out the receptors and the ligands. Clin. Exp. Pharmacol. Physiol. 2013, 40:916-921.
83. Fernandez C.F., Mendoza A.J., Arevalo J.F. Central serous chorioretinopathy associated with topical dermal corticosteroids. Retina (Phila. Pa.) 2004, 24:471-474.
84. Ferrara D., Mohler K.J., Waheed N., Adhi M., Liu J.J., Grulkowski I., Kraus M.F., Baumal C., Hornegger J., Fujimoto J.G., Duker J.S. En face enhanced-depth swept-source optical coherence tomography features of chronic central serous chorioretinopathy. Ophthalmology 2014, 121:719-726.
85. Ficker L., Vafidis G., While A., Leaver P. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br. J. Ophthalmol. 1988, 72:829-834.
86. Fok A.C.T., Chan P.P.M., Lam D.S.C., Lai T.Y.Y. Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res. 2011, 46:160-163.
87. Forooghian F., Meleth A.D., Cukras C., Chew E.Y., Wong W.T., Meyerle C.B. Finasteride for chronic central serous chorioretinopathy. Retina (Phila. Pa.) 2011, 31:766-771.
88. Framme C., Walter A., Gabler B., Roider J., Sachs H.G., Gabel V.-P. Fundus autofluorescence in acute and chronic-recurrent central serous chorioretinopathy. Acta Ophthalmol. Scand. 2005, 83:161-167.
89. Fraunfelder F.W., Fraunfelder F.T. Central serous chorioretinopathy associated with sildenafil. Retina 2008, 28:606-609.
90. Freund K.B., Mrejen S., Jung J., Yannuzzi L.A., Boon C.J.F. Increased fundus autofluorescence related to outer retinal disruption. JAMA Ophthalmol. 2013, 131:1645-1649.
91. Friberg T.R., Eller A.W. Serous retinal detachment resembling central serous chorioretinopathy following organ transplantation. Graefes Arch. Clin. Exp. Ophthalmol. 1990, 228:305-309.
92. Fujimoto H., Gomi F., Wakabayashi T., Sawa M., Tsujikawa M., Tano Y. Morphologic changes in acute central serous chorioretinopathy evaluated by fourier-domain optical coherence tomography. Ophthalmology 2008, 115:1494-1500. 1500.e1-2.
93. Fujiwara T., Imamura Y., Margolis R., Slakter J.S., Spaide R.F. Enhanced depth imaging optical coherence tomography of the choroid in highly myopic eyes. Am. J. Ophthalmol. 2009, 148:445-450.
94. Fuller P.J., Yao Y., Yang J., Young M.J. Mechanisms of ligand specificity of the mineralocorticoid receptor. J.Endocrinol. 2012, 213:15-24.
95. Funder J.W. Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr. Blood Press Control 2013, 6:129-138.
96. Funder J.W. RALES, EPHESUS and redox. J.Steroid Biochem. Mol. Biol. 2005, 93:121-125.
97. Fung A.T., Yannuzzi L.A., Freund K.B. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina (Phila. Pa.) 2012, 32:1829-1837.
98. Furuta M., Iida T., Kishi S. Foveal thickness can predict visual outcome in patients with persistent central serous chorioretinopathy. Ophthalmologica 2009, 223:28-31.
99. Gäckle H.C., Lang G.E., Freissler K.A., Lang G.K. Central serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspects. Ophthalmologe 1998, 95:529-533.
100. Gardiner P., Schrode K., Quinlan D., Martin B.K., Boreham D.R., Rogers M.S., Stubbs K., Smith M., Karim A. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J.Clin. Pharmacol. 1989, 29:342-347.
101. Garg S.P., Dada T., Talwar D., Biswas N.R. Endogenous cortisol profile in patients with central serous chorioretinopathy. Br. J. Ophthalmol. 1997, 81:962-964.
102. Gass J.D., Little H. Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology 1995, 102:737-747.
103. Gaucher D., Erginay A., Lecleire-Collet A., Haouchine B., Puech M., Cohen S.-Y., Massin P., Gaudric A. Dome-shaped macula in eyes with myopic posterior staphyloma. Am. J. Ophthalmol. 2008, 145:909-914.
104. Geltzer A., Turalba A., Vedula S.S. Surgical Implantation of Steroids with Antiangiogenic Characteristics for Treating Neovascular Age-related Macular Degeneration. Cochrane Database Syst Rev 1, CD005022 2013.
105. Georgalas I., Ladas I., Georgopoulos G., Petrou P. Optic disc pit: a review. Graefe's Arch. Clin. Exp. Ophthalmol. 2011, 249:1113-1122.
106. Ghanem C.I., Gómez P.C., Arana M.C., Perassolo M., Delli Carpini G., Luquita M.G., Veggi L.M., Catania V.A., Bengochea L.A., Mottino A.D. Induction of rat intestinal P-glycoprotein by spironolactone and its effect on absorption of orally administered digoxin. J.Pharmacol. Exp. Ther. 2006, 318:1146-1152.
107. Gilbert C.M., Owens S.L., Smith P.D., Fine S.L. Long-term follow-up of central serous chorioretinopathy. Br. J. Ophthalmol. 1984, 68:815-820.
108. Giusti C. Association of Helicobacter pylori with central serous chorioretinopathy: hypotheses regarding pathogenesis. Med. Hypotheses 2004, 63:524-527.
109. Giusti C. Central serous chorioretinopathy: a new extragastric manifestation of Helicobacter pylori?: analysis of a clinical case. Clin. Ter. 2001, 152:393-397.
110. Goktas A. Correlation of subretinal fluid volume with choroidal thickness and macular volume in acute central serous chorioretinopathy. Eye (Lond.) 2014, 28:1431-1436.
111. Golestaneh N., Picaud S., Mirshahi M. The mineralocorticoid receptor in rodent retina: ontogeny and molecular identity. Mol. Vis. 2002, 8:221-225.
112. Golshahi A., Klingmüller D., Holz F.G., Eter N. Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study. Acta Ophthalmol. 2010, 88:576-581.
113. Gomez-Sanchez E., Gomez-Sanchez C.E. The multifaceted mineralocorticoid receptor. Compr. Physiol. 2014, 4:965-994.
114. Gupta M., Singh A.D., Rundle P.A., Rennie I.G. Efficacy of photodynamic therapy in circumscribed choroidal haemangioma. Eye (Lond.) 2004, 18:139-142.
115. Guyer D.R., Yannuzzi L.A., Slakter J.S., Sorenson J.A., Ho A., Orlock D. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch. Ophthalmol. 1994, 112:1057-1062.
116. Haik G.M., Perez L.F., Murtagh J.J. Central serous retinopathy. Consecutive development in daughter and mother. Am. J. Ophthalmol. 1968, 65:612-615.
117. Haimovici R., Gragoudas E.S., Duker J.S., Sjaarda R.N., Eliott D. Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids. Ophthalmology 1997, 104:1653-1660.
118. Haimovici R., Koh S., Gagnon D.R., Lehrfeld T., Wellik S., Central Serous Chorioretinopathy Case-Control Study Group Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004, 111:244-249.
119. Haimovici R., Rumelt S., Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 2003, 110:698-703.
120. Hamzah F., Shinojima A., Mori R., Yuzawa M. Choroidal thickness measurement by enhanced depth imaging and swept-source optical coherence tomography in central serous chorioretinopathy. BMC Ophthalmol. 2014, 14:145.
121. Han J.M., Hwang J.-M., Kim J.S., Park K.H., Woo S.J. Changes in choroidal thickness after systemic administration of high-dose corticosteroids: a pilot study. Invest. Ophthalmol. Vis. Sci. 2014, 55:440-445.
122. Heimann H., Jmor F., Damato B. Imaging of retinal and choroidal vascular tumours. Eye (Lond.) 2013, 27:208-216.
123. Herold T.R., Prause K., Wolf A., Mayer W.J., Ulbig M.W. Spironolactone in the treatment of central serous chorioretinopathy - a case series. Graefes Arch. Clin. Exp. Ophthalmol. 2014, 252:1985-1991.
124. Heylen E., Huang A., Sun D., Kaley G. Nitric oxide-mediated dilation of arterioles to intraluminal administration of aldosterone. J.Cardiovasc. Pharmacol. 2009, 54:535-542.
125. Hirami Y., Tsujikawa A., Sasahara M., Gotoh N., Tamura H., Otani A., Mandai M., Yoshimura N. Alterations of retinal pigment epithelium in central serous chorioretinopathy. Clin. Exp. Ophthalmol. 2007, 35:225-230.
126. How A.C.S.W., Koh A.H.C. Angiographic characteristics of acute central serous chorioretinopathy in an Asian population. Ann. Acad. Med. Singap. 2006, 35:77-79.
127. Hua R., Liu L., Li C., Chen L. Evaluation of the effects of photodynamic therapy on chronic central serous chorioretinopathy based on the mean choroidal thickness and the lumen area of abnormal choroidal vessels. Photodiagnosis Photodyn. Ther. 2014, 11:519-525.
128. Hunter R.G. Epigenetic effects of stress and corticosteroids in the brain. Front. Cell. Neurosci. 2012, 6:18.
129. Hurvitz A.P., Hodapp K.L., Jadgchew J., Solomon D.J., Stolldorf H.S., Provencher M.T. Central serous chorioretinopathy resulting in altered vision and color perception after glenohumeral corticosteroid injection. Orthopedics 2009, 32.
130. Iacono P., Battaglia P.M., Papayannis A., La Spina C., Varano M., Bandello F. Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT. Graefes Arch. Clin. Exp. Ophthalmol. 2015 Jan 8, (Epub ahead of print).
131. Iida T., Kishi S., Hagimura N., Shimizu K. Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina (Phila. Pa.) 1999, 19:508-512.
132. Iida T., Spaide R.F., Negrao S.G., Carvalho C.A., Yannuzzi L.A. Central serous chorioretinopathy after epidural corticosteroid injection. Am. J. Ophthalmol. 2001, 132:423-425.
133. Iida T., Yannuzzi L.A., Spaide R.F., Borodoker N., Carvalho C.A., Negrao S. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina (Phila. Pa.) 2003, 23:1-7. quiz 137-138.
134. Ikuno Y., Kawaguchi K., Nouchi T., Yasuno Y. Choroidal thickness in healthy Japanese subjects. Invest. Ophthalmol. Vis. Sci. 2010, 51:2173-2176.
135. Imamura Y., Fujiwara T., Margolis R., Spaide R.F. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina (Phila. Pa.) 2009, 29:1469-1473.
136. Imamura Y., Fujiwara T., Spaide R.F. Fundus autofluorescence and visual acuity in central serous chorioretinopathy. Ophthalmology 2011, 118:700-705.
137. Imasawa M., Ohshiro T., Gotoh T., Imai M., Iijima H. Central serous chorioretinopathy following vitrectomy with intravitreal triamcinolone acetonide for diabetic macular oedema. Acta Ophthalmol. Scand. 2005, 83:132-133.
138. Inhoffen W., Ziemssen F., Bartz-Schmidt K.U. Chronic central serous chorioretinopathy (cCSC): differential diagnosis to choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD). Klin. Monbl Augenheilkd 2012, 229:889-896.
139. Jain N., Johnson M.W. Pathogenesis and treatment of maculopathy associated with cavitary optic disc anomalies. Am. J. Ophthalmol. 2014, 158:423-435.
140. Jampol L.M., Weinreb R., Yannuzzi L. Involvement of corticosteroids and catecholamines in the pathogenesis of central serous chorioretinopathy: a rationale for new treatment strategies. Ophthalmology 2002, 109:1765-1766.
141. Jirarattanasopa P., Ooto S., Nakata I., Tsujikawa A., Yamashiro K., Oishi A., Yoshimura N. Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy. Invest. Ophthalmol. Vis. Sci. 2012, 53:3663-3672.
142. Jirarattanasopa P., Ooto S., Tsujikawa A., Yamashiro K., Hangai M., Hirata M., Matsumoto A., Yoshimura N. Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy. Ophthalmology 2012, 119:1666-1678.
143. Juruena M.F., Werne Baes C.V., Menezes I.C., Graeff F.G. Early life stress in depressive patients: role of glucocorticoid and mineralocorticoid receptors and of hypothalamic-pituitary-adrenal axis activity. Curr. Pharm. Des. 2015, 21(11):1369-1378.
144. Kamoun R., Zhioua R., Beltaief O., Boussen I., Ouertani A.M. Central serous chorioretinopathy in a kidney transplant patient. J.Fr. Ophtalmol. 2005, 28:51-54.
145. Kang N.H., Kim Y.T. Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy. Eye (Lond.) 2013, 27:387-391.
146. Kao L.Y. Bilateral serous retinal detachment resembling central serous chorioretinopathy following epidural steroid injection. Retina (Phila. Pa.) 1998, 18:479-481.
147. Kapetanios A.D., Donati G., Bouzas E., Mastorakos G., Pournaras C.J. Serous central chorioretinopathy and endogenous hypercortisolemia. Klin. Monbl Augenheilkd 1998, 212:343-344.
148. Karadimas P., Bouzas E.A. Glucocorticoid use represents a risk factor for central serous chorioretinopathy: a prospective, case-control study. Graefes Arch. Clin. Exp. Ophthalmol. 2004, 242:800-802.
149. Karashima K., Fujioka S., Harino S. Two cases of central serous chorioretinopathy treated with photocoagulation after bone marrow transplantation. Retina (Phila. Pa.) 2002, 22:651-653.
150. Kassam A.-A., White W., Ling R.H., Kitson J.B. Loss of visual acuity due to central serous retinopathy after steroid injection into the shoulder bursa. J.Shoulder Elb. Surg. 2011, 20:e5-6.
151. Katsimpris J.M., Pournaras C.J., Sehgelmeble C.W., Petropoulos I.K. Severe bilateral central serous chorioretinopathy in a black patient: 16 years follow-up. Graefes Arch. Clin. Exp. Ophthalmol. 2007, 245:460-463.
152. Keilhauer C.N., Delori F.C. Near-infrared autofluorescence imaging of the fundus: visualization of ocular melanin. Invest. Ophthalmol. Vis. Sci. 2006, 47:3556-3564.
153. Khairallah M., Kahloun R., Tugal-Tutkun I. Central serous chorioretinopathy, corticosteroids, and uveitis. Ocul. Immunol. Inflamm. 2012, 20:76-85.
154. Kian-Ersi F., Taheri S., Akhlaghi M.R. Ocular disorders in renal transplant patients. Saudi J. Kidney Dis. Transpl. 2008, 19:751-755.
155. Kim H.C., Cho W.B., Chung H. Morphologic changes in acute central serous chorioretinopathy using spectral domain optical coherence tomography. Korean J. Ophthalmol. 2012, 26:347-354.
156. Kim J.H., Kang S.W., Kim J.R., Kim S.J. Variability of subfoveal choroidal thickness measurements in patients with age-related macular degeneration and central serous chorioretinopathy. Eye (Lond.) 2013, 27:809-815.
157. Kim S.-K., Kim S.-W., Oh J., Huh K. Near-infrared and short-wavelength autofluorescence in resolved central serous chorioretinopathy: association with outer retinal layer abnormalities. Am. J. Ophthalmol. 2013, 156. 157.e2-164.e2.
158. Kim S.-W., Oh J., Kwon S.-S., Yoo J., Huh K. Comparison of choroidal thickness among patients with healthy eyes, early age-related maculopathy, neovascular age-related macular degeneration, central serous chorioretinopathy, and polypoidal choroidal vasculopathy. Retina (Phila. Pa.) 2011, 31:1904-1911.
159. Kim Y.C., Kim S.D., Kim K.S. Acase of idiopathic central serous chorioretinopathy in a 12-year-old male treated with bevacizumab. Korean J. Ophthalmol. 2012, 26:391-393.
160. Kim Y.T., Kang S.W., Bai K.H. Choroidal thickness in both eyes of patients with unilaterally active central serous chorioretinopathy. Eye (Lond.) 2011, 25:1635-1640.
161. Kitaya N., Nagaoka T., Hikichi T., Sugawara R., Fukui K., Ishiko S., Yoshida A. Features of abnormal choroidal circulation in central serous chorioretinopathy. Br. J. Ophthalmol. 2003, 87:709-712.
162. Kitzmann A.S., Pulido J.S., Diehl N.N., Hodge D.O., Burke J.P. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology 2008, 115:169-173.
163. Kleinberger A.J., Patel C., Lieberman R.M., Malkin B.D. Bilateral central serous chorioretinopathy caused by intranasal corticosteroids: a case report and review of the literature. Laryngoscope 2011, 121:2034-2037.
164. Kloos P., Laube I., Thoelen A. Obstructive sleep apnea in patients with central serous chorioretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246:1225-1228.
165. Kocabora M.S., Durmaz S., Kandemir N. Exacerbation of central serous chorioretinopathy following intravitreal triamcinolone injection. Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246:1783-1786.
166. Koh A.H.C., Expert PCV Panel, Chen L.-J., Chen S.-J., Chen Y., Giridhar A., Iida T., Kim H., Yuk Yau Lai T., Lee W.K., Li X., Han Lim T., Ruamviboonsuk P., Sharma T., Tang S., Yuzawa M. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina (Phila. Pa.) 2013, 33:686-716.
167. Koizumi H., Yamagishi T., Yamazaki T., Kawasaki R., Kinoshita S. Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2011, 249:1123-1128.
168. Konstantinidis L., Mantel I., Zografos L., Ambresin A. Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy. Eur. J. Ophthalmol. 2010, 20:955-958.
169. Kon Y., Iida T., Maruko I., Saito M. The optical coherence tomography-ophthalmoscope for examination of central serous chorioretinopathy with precipitates. Retina (Phila. Pa.) 2008, 28:864-869.
170. Koss M.J., Beger I., Koch F.H. Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye (Lond.) 2012, 26:307-314.
171. Koyama M., Mizota A., Igarashi Y., Adachi-Usami E. Seventeen cases of central serous chorioretinopathy associated with systemic corticosteroid therapy. Ophthalmologica 2004, 218:107-110.
172. Kunavisarut P., Pathanapitoon K., van Schooneveld M., Rothova A. Chronic central serous chorioretinopathy associated with serous retinal detachment in a series of Asian patients. Ocul. Immunol. Inflamm. 2009, 17:269-277.
173. Kuroda S., Ikuno Y., Yasuno Y., Nakai K., Usui S., Sawa M., Tsujikawa M., Gomi F., Nishida K. Choroidal thickness in central serous chorioretinopathy. Retina (Phila. Pa.) 2013, 33:302-308.
174. Kurup S.K., Oliver A., Emanuelli A., Hau V., Callanan D. Low-dose methotrexate for the treatment of chronic central serous chorioretinopathy: a retrospective analysis. Retina (Phila. Pa.) 2012, 32:2096-2101.
175. Lafaut B.A., Salati C., Priem H., De Laey J.J. Indocyanine green angiography is of value for the diagnosis of chronic central serous chorioretinopathy in elderly patients. Graefes Arch. Clin. Exp. Ophthalmol. 1998, 236:513-521.
176. Landa G., Barnett J.A., Garcia P.M.T., Tai K.W., Rosen R.B. Quantitative and qualitative spectral domain optical coherence tomography analysis of subretinal deposits in patients with acute central serous retinopathy. Ophthalmologica 2013, 230:62-68.
177. Lanzetta P., Furlan F., Morgante L., Veritti D., Bandello F. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. Eur. J. Ophthalmol. 2008, 18:934-940.
178. Leaver P., Williams C. Argon laser photocoagulation in the treatment of central serous retinopathy. Br. J. Ophthalmol. 1979, 63:674-677.
179. Lee J.Y., Chae J.B., Yang S.J., Kim J.-G., Yoon Y.H. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy. Acta Ophthalmol. 2011, 89:e293-294.
180. Lehmann M., Bousquet E., Beydoun T., Behar-Cohen F. PACHYCHOROID: an inherited condition?. Retina (Phila. Pa.) 2015, 35:10-16.
181. Lehmann M., Wolff B., Vasseur V., Martinet V., Manasseh N., Sahel J.A., Mauget-Faÿsse M. Retinal and choroidal changes observed with "En face" enhanced-depth imaging OCT in central serous chorioretinopathy. Br. J. Ophthalmol. 2013, 97:1181-1186.
182. Levy J., Marcus M., Belfair N., Klemperer I., Lifshitz T. Central serous chorioretinopathy in patients receiving systemic corticosteroid therapy. Can. J. Ophthalmol. 2005, 40:217-221.
183. Liew G., Quin G., Gillies M., Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology: Central serous chorioretinopathy. Clin. Exp. Ophthalmol. 2013, 41:201-214.
184. Lim J.I., Glassman A.R., Aiello L.P., Chakravarthy U., Flaxel C.J., Spaide R.F., Macula Society CSC Collaborative Study Group, Research and Education Committee and Website Committee Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 2014, 121:1073-1078.
185. Lim J.W., Kang S.W., Kim Y.-T., Chung S.E., Lee S.W. Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy. Br. J. Ophthalmol. 2011, 95:514-517.
186. Lim J.W., Kim M.U. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2011, 249:969-974.
187. Lim J.W., Kim M.U., Shin M.-C. Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy. Retina (Phila. Pa.) 2010, 30:1465-1471.
188. Lim J.W., Ryu S.J., Shin M.C. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J. Ophthalmol. 2010, 24:155-158.
189. Lim Z., Wong D. Retinal pigment epithelial rip associated with idiopathic central serous chorioretinopathy. Eye (Lond.) 2008, 22:471-473.
190. Lin E., Arrigg P.G., Kim R.Y. Familial central serous choroidopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2000, 238:930-931.
191. Li X.Q., Larsen M., Munch I.C. Subfoveal choroidal thickness in relation to sex and axial length in 93 Danish university students. Invest. Ophthalmol. Vis. Sci. 2011, 52:8438-8441.
192. Loo J.-L., Lee S.-Y., Ang C.-L. Can long-term corticosteriods lead to blindness? A case series of central serous chorioretinopathy induced by corticosteroids. Ann. Acad. Med. Singap. 2006, 35:496-499.
193. Loo R.H., Scott I.U., Flynn H.W., Gass J.D.M., Murray T.G., Lewis M.L., Rosenfeld P.J., Smiddy W.E. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina (Phila. Pa.) 2002, 22:19-24.
194. Ma J., Meng N., Xu X., Zhou F., Qu Y. System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol. 2014, 92:e594-601.
195. Mansuetta C.C., Mason J.O., Swanner J., Feist R.M., White M.F., Thomley M.L., McGwin G., Emond T.L. An association between central serous chorioretinopathy and gastroesophageal reflux disease. Am. J. Ophthalmol. 2004, 137:1096-1100.
196. Margolis R., Spaide R.F. Apilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am. J. Ophthalmol. 2009, 147:811-815.
197. Maruko I., Iida T., Ojima A., Sekiryu T. Subretinal dot-like precipitates and yellow material in central serous chorioretinopathy. Retina (Phila. Pa.) 2011, 31:759-765.
198. Maruko I., Iida T., Sugano Y., Furuta M., Sekiryu T. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy. Retina (Phila. Pa.) 2011, 31:1921-1927.
199. Maruko I., Iida T., Sugano Y., Ojima A., Ogasawara M., Spaide R.F. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 2010, 117:1792-1799.
200. Maruko I., Iida T., Sugano Y., Ojima A., Sekiryu T. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina (Phila. Pa.) 2011, 31:1603-1608.
201. Mateo-Montoya A., Mauget-Faÿse M. Helicobacter pylori as a risk factor for central serous chorioretinopathy: literature review. World J. Gastrointest. Pathophysiol. 2014, 5:355-358.
202. Matsumoto H., Kishi S., Otani T., Sato T. Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am. J. Ophthalmol. 2008, 145:162-168.
203. Matsumoto H., Kishi S., Sato T., Mukai R. Fundus autofluorescence of elongated photoreceptor outer segments in central serous chorioretinopathy. Am. J. Ophthalmol. 2011, 151. 617.e1-623.e1.
204. Matsumoto H., Sato T., Kishi S. Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous chorioretinopathy. Am. J. Ophthalmol. 2009, 148. 105.e1-110.e1.
205. Mauget-Faÿsse M., Kodjikian L., Quaranta M., Ben Ezra D., Trepsat C., Mion F., Mégraud F. Helicobacter pylori in central serous chorioretinopathy and diffuse retinal epitheliopathy. Results of the first prospective pilot study. J.Fr. Ophtalmol. 2002, 25:1021-1025.
206. Mazzolani F., Togni S. Oral administration of a curcumin-phospholipid delivery system for the treatment of central serous chorioretinopathy: a 12-month follow-up study. Clin. Ophthalmol. 2013, 7:939-945.
207. McCannel T.A., Chmielowski B., Finn R.S., Goldman J., Ribas A., Wainberg Z.A., McCannel C.A. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol. 2014, 132:1005-1009.
208. McCurley A., Jaffe I.Z. Mineralocorticoid receptors in vascular function and disease. Mol. Cell. Endocrinol. 2012, 350:256-265.
209. McGraw A.P., Bagley J., Chen W.-S., Galayda C., Nickerson H., Armani A., Caprio M., Carmeliet P., Jaffe I.Z. Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism. J.Am. Heart Assoc. 2013, 2:e000018.
210. Michael J.C., Pak J., Pulido J., de Venecia G. Central serous chorioretinopathy associated with administration of sympathomimetic agents. Am. J. Ophthalmol. 2003, 136:182-185.
211. Mihailidou A.S., Ashton A.W. Cardiac effects of aldosterone: does gender matter?. Steroids 2014, 91:32-37.
212. Miki A., Kondo N., Yanagisawa S., Bessho H., Honda S., Negi A. Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology 2014 May, 121(5):1067-1072.
213. Mitarai K., Gomi F., Tano Y. Three-dimensional optical coherence tomographic findings in central serous chorioretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2006, 244:1415-1420.
214. Mondal L.K., Sarkar K., Datta H., Chatterjee P.R. Acute bilateral central serous chorioretinopathy following intra-articular injection of corticosteroid. Indian J. Ophthalmol. 2005, 53:132-134.
215. Moon S.J., Mieler W.F. Retinal complications of bone marrow and solid organ transplantation. Curr. Opin. Ophthalmol. 2003, 14:433-442.
216. Mrejen S., Sarraf D., Mukkamala S.K., Freund K.B. Multimodal imaging of pigment epithelial detachment: a guide to evaluation. Retina (Phila. Pa.) 2013, 33:1735-1762.
217. Mrejen S., Spaide R.F. Optical coherence tomography: imaging of the choroid and beyond. Surv. Ophthalmol. 2013, 58:387-429.
218. Mudvari S.S., Goff M.J., Fu A.D., McDonald H.R., Johnson R.N., Ai E., Jumper J.M. The natural history of pigment epithelial detachment associated with central serous chorioretinopathy. Retina (Phila. Pa.) 2007, 27:1168-1173.
219. Nguyen Dinh Cat A., Griol-Charhbili V., Loufrani L., Labat C., Benjamin L., Farman N., Lacolley P., Henrion D., Jaisser F. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J. 2010, 24:2454-2463.
220. Nguyen Dinh Cat A., Jaisser F. Extrarenal effects of aldosterone. Curr. Opin. Nephrol. Hypertens. 2012, 21:147-156.
221. Nicholson B., Noble J., Forooghian F., Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv. Ophthalmol. 2013, 58:103-126.
222. Nicoló M., Eandi C.M., Alovisi C., Grignolo F.M., Traverso C.E., Musetti D., Cardillo Piccolino F. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am. J. Ophthalmol. 2014, 157:1033-1037.
223. Nielsen J.S., Jampol L.M. Oral mifepristone for chronic central serous chorioretinopathy. Retina (Phila. Pa.) 2011, 31:1928-1936.
224. Noma H., Funatsu H., Mimura T., Shimada K. Comparison of the efficacy of intravitreal triamcinolone acetonide for cystoid macular edema with versus without serous retinal detachment in branch retinal vein occlusion: influence on macular sensitivity and morphology. BMC Ophthalmol. 2012, 12:39.
225. Odermatt A., Atanasov A.G. Mineralocorticoid receptors: emerging complexity and functional diversity. Steroids 2009, 74:163-171.
226. Oh J.-H., Oh J., Togloom A., Kim S.-W., Huh K. Biometric characteristics of eyes with central serous chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2014, 55:1502-1508.
227. Ojima Y., Hangai M., Sasahara M., Gotoh N., Inoue R., Yasuno Y., Makita S., Yatagai T., Tsujikawa A., Yoshimura N. Three-dimensional imaging of the foveal photoreceptor layer in central serous chorioretinopathy using high-speed optical coherence tomography. Ophthalmology 2007, 114:2197-2207.
228. Oliaei F., Rasoulinejad A., Seifi B. An ophthalmological complication: central serous chorioretinopathy in a renal transplant recipient. Transpl. Proc. 2007, 39:1134-1135.
229. Oosterhuis J.A. Familial central serous retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 1996, 234:337-341.
230. Ooto S., Hangai M., Sakamoto A., Tsujikawa A., Yamashiro K., Ojima Y., Yamada Y., Mukai H., Oshima S., Inoue T., Yoshimura N. High-resolution imaging of resolved central serous chorioretinopathy using adaptive optics scanning laser ophthalmoscopy. Ophthalmology 2010, 117:1800-1809. 1809.e1-2.
231. Ooto S., Tsujikawa A., Mori S., Tamura H., Yamashiro K., Otani A., Yoshimura N. Retinal microstructural abnormalities in central serous chorioretinopathy and polypoidal choroidal vasculopathy. Retina (Phila. Pa.) 2011, 31:527-534.
232. Ooto S., Tsujikawa A., Mori S., Tamura H., Yamashiro K., Yoshimura N. Thickness of photoreceptor layers in polypoidal choroidal vasculopathy and central serous chorioretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2010, 248:1077-1086.
233. Ossewaarde-van Norel J., Berg E.M., Sijssens K.M., Rothova A. Subfoveal serous retinal detachment in patients with uveitic macular edema. Arch. Ophthalmol. 2011, 129:158-162.
234. Pang C.E., Freund K.B. Pachychoroid neovasculopathy. Retina (Phila. Pa.) 2015, 35:1-9.
235. Park D.W., Schatz H., Gaffney M.M., McDonald H.R., Johnson R.N., Schaeffer D. Central serous chorioretinopathy in two families. Eur. J. Ophthalmol. 1998, 8:42-47.
236. Park S.J., Kim B.H., Park K.H., Woo S.J. Punctate hyperfluorescence spot as a common choroidopathy of central serous chorioretinopathy and polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2014 Dec, 158(6):1155-1163.
237. Perkins S.L., Kim J.E., Pollack J.S., Merrill P.T. Clinical characteristics of central serous chorioretinopathy in women. Ophthalmology 2002, 109:262-266.
238. Piccolino F.C., Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina (Phila. Pa.) 1994, 14:231-242.
239. Piccolino F.C., De La Longrais R.R., Manea M., Cicinelli S. Posterior cystoid retinal degeneration in central serous chorioretinopathy. Retina (Phila. Pa.) 2008, 28:1008-1012.
240. Piccolino F.C., De La Longrais R.R., Manea M., Cicinelli S., Ravera G. Risk factors for posterior cystoid retinal degeneration in central serous chorioretinopathy. Retina (Phila. Pa.) 2008, 28:1146-1150.
241. Piccolino F.C., de la Longrais R.R., Ravera G., Eandi C.M., Ventre L., Abdollahi A., Manea M. The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. Am. J. Ophthalmol. 2005, 139:87-99.
242. Pierce K.K., Lane R.G. Central serous chorioretinopathy associated with the use of ephedra. Retin Cases Brief. Rep. 2009, 3:376-378.
243. Pikkel J., Beiran I., Ophir A., Miller B. Acetazolamide for central serous retinopathy. Ophthalmology 2002, 109:1723-1725.
244. Piskunowicz M., Jaracz M., Lesiewska H., Malukiewicz G., Brozek-Pestka M., Borkowska A. Temperament profile in patients with central serous chorioretinopathy: a case-control study. Eur. J. Ophthalmol. 2014, 24:392-395.
245. Pitcher J.D., Witkin A.J., DeCroos F.C., Ho A.C. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study. Br. J. Ophthalmol. 2015 Jun, 99(6):848-852.
246. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M., Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N.Engl. J. Med. 2003, 348:1309-1321.
247. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N.Engl. J. Med. 1999, 341:709-717.
248. Pizzimenti J.J., Daniel K.P. Central serous chorioretinopathy after epidural steroid injection. Pharmacotherapy 2005, 25:1141-1146.
249. Plateroti A.M., Witmer M.T., Kiss S., D'Amico D.J. Characteristics of intraretinal deposits in acute central serous chorioretinopathy. Clin. Ophthalmol. 2014, 8:673-676.
250. Polak B.C., Baarsma G.S., Snyers B. Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment. Br. J. Ophthalmol. 1995, 79:922-925.
251. Prünte C. Indocyanine green angiographic findings in central serous chorioretinopathy. Int. Ophthalmol. 1995, 19:77-82.
252. Pryds A., Larsen M. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy. Acta Ophthalmol. 2012, 90:738-743.
253. Quillen D.A., Gass D.M., Brod R.D., Gardner T.W., Blankenship G.W., Gottlieb J.L. Central serous chorioretinopathy in women. Ophthalmology 1996, 103:72-79.
254. Quin G., Liew G., Ho I.-V., Gillies M., Fraser-Bell S. Diagnosis and interventions for central serous chorioretinopathy: review and update. Clin. Exp. Ophthalmol. 2013, 41:187-200.
255. Rahbani-Nobar M.B., Javadzadeh A., Ghojazadeh L., Rafeey M., Ghorbanihaghjo A. The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol. Vis. 2011, 17:99-103.
256. Razavi S., Souied E.H., Cavallero E., Weber M., Querques G. Assessment of choroidal topographic changes by swept source optical coherence tomography after photodynamic therapy for central serous chorioretinopathy. Am. J. Ophthalmol. 2014, 157:852-860.
257. Reibaldi M., Cardascia N., Longo A., Furino C., Avitabile T., Faro S., Sanfilippo M., Russo A., Uva M.G., Munno F., Cannemi V., Zagari M., Boscia F. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am. J. Ophthalmol. 2010, 149. 307.e2-315.e2.
258. Reynolds R.M. Glucocorticoid excess and the developmental origins of disease: two decades of testing the hypothesis-2012 Curt Richter Award Winner. Psychoneuroendocrinology 2013, 38:1-11.
259. Rishi P., Rishi E., Mathur G., Raval V. Ocular perfusion pressure and choroidal thickness in eyes with polypoidal choroidal vasculopathy, wet-age-related macular degeneration, and normals. Eye (Lond.) 2013, 27:1038-1043.
260. Robertson D.M., Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am. J. Ophthalmol. 1983, 95:457-466.
261. Roisman L., Magalhães F.P., Lavinsky D., Moraes N., Hirai F.E., Cardillo J.A., Farah M.E. Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial. Ophthalmic Surg. Lasers Imaging Retina 2013, 44:465-470.
262. Romero P., Martinez I., Salvat M. Diffuse retinal pigment epitheliopathy and corticoid ointment topical treatment in a patient with psoriasis. J.Fr. Ophtalmol. 2005, 28:1101-1104.
263. Roshani M., Davoodi N.A., Seyyedmajidi M.R., Zojaji H., Sherafat S.J., Hashemi M., Zali M.R. Association of Helicobacter pylori with central serous chorioretinopathy in Iranian patients. Gastroenterol. Hepatol. Bed Bench 2014, 7:63-67.
264. Ross A., Ross A.H., Mohamed Q. Review and update of central serous chorioretinopathy. Curr. Opin. Ophthalmol. 2011, 22:166-173.
265. Sabet-Peyman J., Salehi-Had H., Fawzi A.A. Multimodal imaging in a case of central serous chorioretinopathy following renal transplantation. Ophthalmic Surg. Lasers Imaging 43 Online 2012, e58-61.
266. Saito M., Saito W., Hashimoto Y., Yoshizawa C., Fujiya A., Noda K., Ishida S. Macular choroidal blood flow velocity decreases with regression of acute central serous chorioretinopathy. Br. J. Ophthalmol. 2013, 97:775-780.
267. Salvador E., Shityakov S., Förster C. Glucocorticoids and endothelial cell barrier function. Cell. Tissue Res. 2014, 355:597-605.
268. Sarao V., Veritti D., Boscia F., Lanzetta P. Intravitreal steroids for the treatment of retinal diseases. ScientificWorldJournal 2014, 2014:989501.
269. Sasahara M., Tsujikawa A., Musashi K., Gotoh N., Otani A., Mandai M., Yoshimura N. Polypoidal choroidal vasculopathy with choroidal vascular hyperpermeability. Am. J. Ophthalmol. 2006, 142:601-607.
270. Schaal K.B., Hoeh A.E., Scheuerle A., Schuett F., Dithmar S. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur. J. Ophthalmol. 2009, 19:613-617.
271. Schatz H., Madeira D., Johnson R.N., McDonald H.R. Central serous chorioretinopathy occurring in patients 60 years of age and older. Ophthalmology 1992, 99:63-67.
272. Scheider A., Nasemann J.E., Lund O.E. Fluorescein and indocyanine green angiographies of central serous choroidopathy by scanning laser ophthalmoscopy. Am. J. Ophthalmol. 1993, 115:50-56.
273. Schlötzer-Schrehardt U., Viestenz A., Naumann G.O.H., Laqua H., Michels S., Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch. Clin. Exp. Ophthalmol. 2002, 240:748-757.
274. Schubert C., Pryds A., Zeng S., Xie Y., Freund K.B., Spaide R.F., Merriam J.C., Barbazetto I., Slakter J.S., Chang S., Munch I.C., Drack A.V., Hernandez J., Yzer S., Merriam J.E., Linneberg A., Larsen M., Yannuzzi L.A., Mullins R.F., Allikmets R. Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. Hum. Mutat. 2014 Jul, 35(7):859-867. 10.1002/humu.22551.
275. Sekiryu T., Iida T., Maruko I., Saito K., Kondo T. Infrared fundus autofluorescence and central serous chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2010, 51:4956-4962.
276. Semeraro F., Romano M.R., Danzi P., Morescalchi F., Costagliola C. Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy. Jpn. J. Ophthalmol. 2012, 56:608-612.
277. Senturk F., Karacorlu M., Ozdemir H., Karacorlu S.A., Uysal O. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Am. J. Ophthalmol. 2011, 151. 303.e1-309.e1.
278. Sharma T., Shah N., Rao M., Gopal L., Shanmugam M.P., Gopalakrishnan M., Bhende P., Bhende M., Shetty N.S., Baluswamy S. Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology 2004, 111:1708-1714.
279. Shields C.L., Honavar S.G., Shields J.A., Cater J., Demirci H. Circumscribed choroidal hemangioma: clinical manifestations and factors predictive of visual outcome in 200 consecutive cases. Ophthalmology 2001, 108:2237-2248.
280. Shields C.L., Pellegrini M., Ferenczy S.R., Shields J.A. Enhanced depth imaging optical coherence tomography of intraocular tumors: from placid to seasick to rock and rolling topography-the 2013 Francesco Orzalesi Lecture. Retina (Phila. Pa.) 2014, 34:1495-1512.
281. Shin J.Y., Woo S.J., Yu H.G., Park K.H. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina (Phila. Pa.) 2011, 31:119-126.
282. Shin M.C., Lim J.W. Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy. Retina (Phila. Pa.) 2011, 31:1937-1943.
283. Shinojima A., Hirose T., Mori R., Kawamura A., Yuzawa M. Morphologic findings in acute central serous chorioretinopathy using spectral domain-optical coherence tomography with simultaneous angiography. Retina (Phila. Pa.) 2010, 30:193-202.
284. Shin Y.U., Lee B.R. Retro-mode imaging for retinal pigment epithelium alterations in central serous chorioretinopathy. Am. J. Ophthalmol. 2012, 154. 155.e4-163.e4.
285. Sibayan S.A., Kobuch K., Spiegel D., Eckert E., Leser R., Monzer J., Gabel V.P. Epinephrine, but not dexamethasone, induces apoptosis in retinal pigment epithelium cells invitro: possible implications on the pathogenesis of central serous chorioretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2000, 238:515-519.
286. Simon P., Glacet-Bernard A., Binaghi M., Coscas G., Soubrane G. Choroidal neovascularization as a complication following laser treatment of central serous chorioretinopathy. J.Fr. Ophtalmol. 2001, 24:64-68.
287. Singh A.D., Demirci H., Shields C.L., Shields J.A. Central serous chorioretinopathy as a complication of postcardiac transplant corticosteroid therapy. Eye (Lond.) 2003, 17:522-524.
288. Spaide R.F., Campeas L., Haas A., Yannuzzi L.A., Fisher Y.L., Guyer D.R., Slakter J.S., Sorenson J.A., Orlock D.A. Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996, 103:2070-2079. discussion 2079-2080.
289. Spaide R.F., Hall L., Haas A., Campeas L., Yannuzzi L.A., Fisher Y.L., Guyer D.R., Slakter J.S., Sorenson J.A., Orlock D.A. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina (Phila. Pa.) 1996, 16:203-213.
290. Spaide R.F., Klancnik J.M. Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology 2005, 112:825-833.
291. Spraul C.W., Lang G.E., Lang G.K. Retinal pigment epithelial changes associated with systemic corticosteroid treatment: report of cases and review of the literature. Ophthalmologica 1998, 212:142-148.
292. Spraul C.W., Lang G.E., Lang G.K. Central serous chorioretinopathy in systemic therapy with corticosteroids. Ophthalmologe 1997, 94:392-396.
293. Suzuki M., Gomi F., Hara C., Sawa M., Nishida K. Characteristics of central serous chorioretinopathy complicated by focal choroidal excavation. Retina (Phila. Pa.) 2014, 34:1216-1222.
294. Tada Y., Kitazato K.T., Tamura T., Yagi K., Shimada K., Kinouchi T., Satomi J., Nagahiro S. Role of mineralocorticoid receptor on experimental cerebral aneurysms in rats. Hypertension 2009, 54:552-557.
295. Tamura N., Sakai T., Tsuneoka H. Spontaneous resolution of foveal detachment in dome-shaped macula observed by spectral domain optical coherence tomography. Clin. Ophthalmol. 2014, 8:83-86.
296. Teke M.Y., Elgin U., Nalcacioglu-Yuksekkaya P., Sen E., Ozdal P., Ozturk F. Comparison of autofluorescence and optical coherence tomography findings in acute and chronic central serous chorioretinopathy. Int. J. Ophthalmol. 2014, 7:350-354.
297. Ter Heegde F., De Rijk R.H., Vinkers C.H. The brain mineralocorticoid receptor and stress resilience. Psychoneuroendocrinology 2015, 52C:92-110.
298. Tewari H.K., Gadia R., Kumar D., Venkatesh P., Garg S.P. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest. Ophthalmol. Vis. Sci. 2006, 47:3474-3478.
299. Thinda S., Lam K., Park S.S. Unintentional secondary exogenous corticosteroid exposure and central serous chorioretinopathy. Eye (Lond) 2015 Apr, 29(4):577-579. (Epub 2015 Jan 16). 10.1038/eye.2014.328.
300. Tittl M.K., Spaide R.F., Wong D., Pilotto E., Yannuzzi L.A., Fisher Y.L., Freund B., Guyer D.R., Slakter J.S., Sorenson J.A. Systemic findings associated with central serous chorioretinopathy. Am. J. Ophthalmol. 1999, 128:63-68.
301. Tittl M., Maar N., Polska E., Weigert G., Stur M., Schmetterer L. Choroidal hemodynamic changes during isometric exercise in patients with inactive central serous chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2005, 46:4717-4721.
302. Tittl M., Polska E., Kircher K., Kruger A., Maar N., Stur M., Schmetterer L. Topical fundus pulsation measurement in patients with active central serous chorioretinopathy. Arch. Ophthalmol. 2003, 121:975-978.
303. Toyama T., Ohtomo K., Noda Y., Ueta T. Polypoidal choroidal vasculopathy and history of central serous chorioretinopathy. Eye (Lond.) 2014, 28:992-997.
304. Tsai D.-C., Chen S.-J., Huang C.-C., Chou P., Chung C.-M., Chan W.-L., Huang P.-H., Lin S.-J., Chen J.-W., Chen T.-J., Leu H.-B. Risk of central serous chorioretinopathy in adults prescribed oral corticosteroids: a population-based study in Taiwan. Retina (Phila. Pa.) 2014, 34:1867-1874.
305. Tsai D.-C., Chen S.-J., Huang C.-C., Chou P., Chung C.-M., Huang P.-H., Lin S.-J., Chen J.-W., Chen T.-J., Leu H.-B., Chan W.-L. Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study. PLoS One 2013, 8:e66858.
306. Tsai D.-C., Huang C.-C., Chen S.-J., Chou P., Chung C.-M., Chan W.-L., Huang P.-H., Chen T.-J., Lin S.-J., Chen J.-W., Leu H.-B. Central serous chorioretinopathy and risk of ischaemic stroke: a population-based cohort study. Br. J. Ophthalmol. 2012, 96:1484-1488.
307. Tsai D.-C., Huang C.-C., Chen S.-J., Chou P., Chung C.-M., Chan W.-L., Huang P.-H., Lin S.-J., Chen J.-W., Leu H.-B. Increased risk of erectile dysfunction among males with central serous chorioretinopathy - a retrospective cohort study. Acta Ophthalmol. 2013, 91:666-671.
308. Tsujikawa A., Ojima Y., Yamashiro K., Ooto S., Tamura H., Nakagawa S., Yoshimura N. Punctate hyperfluorescent spots associated with central serous chorioretinopathy as seen on indocyanine green angiography. Retina (Phila. Pa.) 2010, 30:801-809.
309. Uetani R., Ito Y., Oiwa K., Ishikawa K., Terasaki H. Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy. Eye (Lond.) 2012, 26:640-649.
310. Urner-Bloch U., Urner M., Stieger P., Galliker N., Winterton N., Zubel A., Moutouh-de Parseval L., Dummer R., Goldinger S.M. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann. Oncol. 2014, 25:1437-1441.
311. Uyama M., Matsunaga H., Matsubara T., Fukushima I., Takahashi K., Nishimura T. Indocyanine green angiography and pathophysiology of multifocal posterior pigment epitheliopathy. Retina (Phila. Pa.) 1999, 19:12-21.
312. Van Velthoven M.E.J., Verbraak F.D., Garcia P.M., Schlingemann R.O., Rosen R.B., de Smet M.D. Evaluation of central serous retinopathy with en face optical coherence tomography. Br. J. Ophthalmol. 2005, 89:1483-1488.
313. Verma L., Sinha R., Venkatesh P., Tewari H.K. Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial [ISRCTN84128484]. BMC Ophthalmol. 2004, 4:15.
314. Viola F., Dell'Arti L., Benatti E., Invernizzi A., Mapelli C., Ferrari F., Ratiglia R., Staurenghi G., Barteselli G. Choroidal findings in dome-shaped macula in highly myopic eyes: a longitudinal study. Am. J. Ophthalmol. 2015, 159:44-52.
315. Von Rückmann A., Fitzke F.W., Fan J., Halfyard A., Bird A.C. Abnormalities of fundus autofluorescence in central serous retinopathy. Am. J. Ophthalmol. 2002, 133:780-786.
316. Wakakura M., Ishikawa S. Central serous chorioretinopathy complicating systemic corticosteroid treatment. Br. J. Ophthalmol. 1984, 68:329-331.
317. Wakakura M., Song E., Ishikawa S. Corticosteroid-induced central serous chorioretinopathy. Jpn. J. Ophthalmol. 1997, 41:180-185.
318. Walker B.R., Best R., Shackleton C.H., Padfield P.L., Edwards C.R. Increased vasoconstrictor sensitivity to glucocorticoids in essential hypertension. Hypertension 1996, 27:190-196.
319. Wang M., Munch I.C., Hasler P.W., Prünte C., Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008, 86:126-145.
320. Wang M., Sander B., la Cour M., Larsen M. Clinical characteristics of subretinal deposits in central serous chorioretinopathy. Acta Ophthalmol. Scand. 2005, 83:691-696.
321. Warrow D.J., Hoang Q.V., Freund K.B. Pachychoroid pigment epitheliopathy. Retina (Phila. Pa.) 2013, 33:1659-1672.
322. Weenink A.C., Borsje R.A., Oosterhuis J.A. Familial chronic central serous chorioretinopathy. Ophthalmologica 2001, 215:183-187.
323. Wei W.B., Xu L., Jonas J.B., Shao L., Du K.F., Wang S., Chen C.X., Xu J., Wang Y.X., Zhou J.Q., You Q.S. Subfoveal choroidal thickness: the Beijing Eye Study. Ophthalmology 2013, 120:175-180.
324. Wilkinson-Berka J.L., Tan G., Jaworski K., Miller A.G. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ. Res. 2009, 104:124-133.
325. Williamson J., Nuki G. Macular lesions during systemic therapy with depot tetracosactrin. Br. J. Ophthalmol. 1970, 54:405-409.
326. Wu Z.H.Y., Lai R.Y.K., Yip Y.W.Y., Chan W.M., Lam D.S.C., Lai T.Y.Y. Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. Retina (Phila. Pa.) 2011, 31:1378-1386.
327. Wyman G.J. Central serous retinopathy in twins. Am. J. Ophthalmol. 1963, 55:1265.
328. Yalcinbayir O., Gelisken O., Akova-Budak B., Ozkaya G., Gorkem Cevik S., Yucel A.A. Correlation of spectral domain optical coherence tomography findings and visual acuity in central serous chorioretinopathy. Retina (Phila. Pa.) 2014, 34:705-712.
329. Yang L., Jonas J.B., Wei W. Optical coherence tomography-assisted enhanced depth imaging of central serous chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2013, 54:4659-4665.
330. Yang L., Jonas J.B., Wei W. Choroidal vessel diameter in central serous chorioretinopathy. Acta Ophthalmol. 2013, 91:e358-362.
331. Yannuzzi L.A. Indocyanine green angiography: a perspective on use in the clinical setting. Am. J. Ophthalmol. 2011, 151. 745.e1-751.e1.
332. Yannuzzi L.A. Central serous chorioretinopathy: a personal perspective. Am. J. Ophthalmol. 2010, 149:361-363.
333. Yannuzzi L.A. Type-A behavior and central serous chorioretinopathy. Retina (Phila. Pa.) 1987, 7:111-131.
334. Yannuzzi L.A. Type A behavior and central serous chorioretinopathy. Trans. Am. Ophthalmol. Soc. 1986, 84:799-845.
335. Yannuzzi L.A., Freund K.B., Goldbaum M., Scassellati-Sforzolini B., Guyer D.R., Spaide R.F., Maberley D., Wong D.W.K., Slakter J.S., Sorenson J.A., Fisher Y.L., Orlock D.A. Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy. Ophthalmology 2000, 107:767-777.
336. Yannuzzi L.A., Shakin J.L., Fisher Y.L., Altomonte M.A. Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology 1984, 91:1554-1572.
337. Yannuzzi L.A., Slakter J.S., Kaufman S.R., Gupta K. Laser treatment of diffuse retinal pigment epitheliopathy. Eur. J. Ophthalmol. 1992, 2:103-114.
338. Yoshioka H., Katsume Y., Akune H. Experimental central serous chorioretinopathy in monkey eyes: fluorescein angiographic findings. Ophthalmologica 1982, 185:168-178.
339. Young M.J., Rickard A.J. Mineralocorticoid receptors in the heart: lessons from cell-selective transgenic animals. J.Endocrinol. 2015, 224:R1-R13.
340. Zakir S.M., Shukla M., Simi Z.-U.-R., Ahmad J., Sajid M. Serum cortisol and testosterone levels in idiopathic central serous chorioretinopathy. Indian J. Ophthalmol. 2009, 57:419-422.
341. Zhao M., Bousquet E., Valamanesh F., Farman N., Jeanny J.-C., Jaisser F., Behar-Cohen F.F. Differential regulations of AQP4 and Kir4.1 by triamcinolone acetonide and dexamethasone in the healthy and inflamed retina. Invest. Ophthalmol. Vis. Sci. 2011, 52:6340-6347.
342. Zhao M., Célérier I., Bousquet E., Jeanny J.-C., Jonet L., Savoldelli M., Offret O., Curan A., Farman N., Jaisser F., Behar-Cohen F. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J.Clin. Invest 2012, 122:2672-2679.
343. Zhao M., Valamanesh F., Celerier I., Savoldelli M., Jonet L., Jeanny J.-C., Jaisser F., Farman N., Behar-Cohen F. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Müller glial cells. FASEB J. 2010, 24:3405-3415.